We work with regulated organisations across life sciences, biotechnology and genomic research — wherever the consequences of compromised data are too high to accept.
Regulators are asking harder questions about data integrity. Audit trails must be complete. Provenance must be defensible. Inspection readiness is no longer a project — it's a permanent state. Most data systems were designed for collection. Few were designed for the standard regulators now apply.
Biotech companies generate years of data across discovery, translational research, process development and commercial manufacturing. That data needs to remain coherent, defensible and verifiable — through partner changes, platform changes, scale-up changes and regulator scrutiny. Most biotech data lives across fragmented systems. The audit trail breaks at every transition.
Genomic research increasingly happens across borders, across institutions and across regulatory regimes. The data is sensitive. The collaborations are political. The audit expectations are rising. Legacy research data systems were not built for this — they force trade-offs between access, anonymity, sovereignty and integrity. The BioChain is the infrastructure layer that resolves those trade-offs.
Public health, agritech, food safety, environmental research — if your work depends on biological data integrity, we should talk.